Targeted Reversible Covalent Modification of a Noncatalytic Lysine of the Krev Interaction Trapped 1 Protein Enables Site-Directed Screening for Protein–Protein Interaction Inhibitors

Karol R. Francisco, Jessica Bruystens, Carmine Varricchio, Sara McCurdy, Jian Wu, Miguel A. Lopez-Ramirez, Mark Ginsberg, Conor R. Caffrey, Andrea Brancale, Alexandre R. Gingras,* Mark S. Hixon,* and Carlo Ballatore*

ABSTRACT: The covalent reversible modification of proteins is a validated strategy for the development of probes and candidate therapeutics. However, the covalent reversible targeting of noncatalytic lysines is particularly challenging. Herein, we characterize the 2-hydroxy-1-naphthaldehyde (HNA) fragment as a targeted covalent reversible ligand of a noncatalytic lysine (Lys\(^{20}\)) of the Krev interaction trapped 1 (KRIT1) protein. We show that the interaction of HNA with KRIT1 is highly specific, results in prolonged residence time of >8 h, and inhibits the Heart of glass 1 (HEG1)–KRIT1 protein–protein interaction (PPI). Screening of HNA derivatives identified analogs exhibiting similar binding modes as the parent fragment but faster target engagement and stronger inhibition activity. These results demonstrate that HNA is an efficient site-directing fragment with promise in developing HEG1-KRIT1 PPI inhibitors. Further, the aldime chemistry, when coupled with templating effects that promote proximity, can produce a long-lasting reversible covalent modification of noncatalytic lysines.

KEYWORDS: protein–protein interaction, noncatalytic lysine, targeted covalent modification, covalent reversible ligand, inhibition kinetics

The development and deployment of amino acid-specific, reversible, covalent fragments is a promising strategy for drug and probe discovery.\(^1\) The reversible nature of the covalent interaction can be beneficial to attain relatively tight binding without causing permanent modification of the target protein or other off-targets. However, a central challenge for this strategy’s success is optimizing the on- and off-rates such that the desired selectivity and duration of action can be obtained. In recent years, there has been growing interest in developing strategies for the reversible covalent modification of the lysine side-chain.\(^2\)–\(^4\) Because lysines are mostly protonated at physiological pH\(_{1}\), targeting this amino acid with electrophiles generally requires local pK\(_a\) perturbations to unmask the nucleophilicity of the ε-amino group. The environment within the active site of enzymes often produces pK\(_a\) perturbations of lysine residues necessary to carry out the enzymatic function. These catalytic lysines are, therefore, generally prone to react with electrophiles. However, in the case of noncatalytic, solvent-exposed lysines that are not inherently reactive, the situation is considerably more challenging.\(^5\)

Different aldehydes can form imine adducts with the ε-amino group of lysine even at physiological pH.\(^6\) However, the dissociation kinetics of the resulting Schiff bases are typically fast under aqueous conditions.\(^7\) The rapid reversibility of the imine formation can be a desirable feature, especially regarding interactions with off-target proteins. However, for the intended target protein, rapid dissociation kinetics imply a short duration of action. Activating and/or trapping functionalities can be employed to promote the formation and/or enhance the stability of imine adducts and, thus, increase the residence time. For example, the presence of a hydroxyl group, a boronic acid, or an aminomethyl-phenylboronic acid in the ortho position of a benzaldehyde has been successfully shown to stabilize or trap the imine adduct through intramolecular H-bonding (e.g., voxelotor\(^8\)) or through the formation of iminoboronate\(^9\) and diazaborine\(^9\) adducts, respectively (Figure 1A,B; for additional examples see refs 10–12). The binding kinetics of iminoboronate- or diazaborine-forming warheads and free lysine, or a noncatalytic lysine residue within a target protein, have been investigated.\(^3\)\(^,\)\(^9\) In contrast, similar studies...
KRIT1 and the Heart of glass 1 (HEG1) protein. inhibitors of the protein of the Krev interaction trapped 1 (KRIT1) protein, and as model systems involving 2-hydroxy-arylaldehydes have only been conducted in

Here, we evaluate the binding kinetics of HNA inhibitors, a fluorescence polarization (FP) time-resolved assay that uses a recombinant FERM domain (residues 417–736) of KRIT1 and a fluorescence-tagged HEG1 cytoplasmic tail (Cy5-HEG1 7-mer peptide) was developed (Supporting Information). Using HNA as a test compound, the FP data, expressed as millipolarization (mP) units, were obtained every 10 min over the course of 4–7 h. The binding affinity ($K_D$) for KRIT1 for the HEG1 probe was examined by following the change in polarization signal as a function of a matrix of five probe concentrations and four KRIT1 concentrations, which produced a best-fit probe $K_D$ of 13 nM. Evaluation of the kinetics of HNA as a KRIT1-HNA inhibitor using the FP assay suggested that, at lower HNA concentrations (<3 μM), equilibrium could not be reached, even after 7 h of incubation. Thus, for practical purposes, a 4-h incubation time was established as the standard assay time for non-kinetic $IC_{50}$ evaluations. From these FP assay conditions, the dose–response curve of HNA resulted in an $IC_{50}$ value of 8.14 μM, comparable to previously reported data obtained using the flow cytometry assay (3.09 μM).14

The HNA-KRIT1 Interaction Demonstrates a Relatively High Specificity and Selectivity. To evaluate the specificity and selectivity of the HNA binding to KRIT1, we asked whether the imine formation between HNA and Lys$^{720}$ was driven primarily by the intrinsic reactivity of the aldehyde moiety or the KRIT1 Lys$^{720}$. We first determined whether the inhibition activity of the HNA inhibitor could be reduced upon co-incubation of the compound with free lysine (50 μM) in the assay buffer. These co-incubation experiments revealed that the inhibition of HEG1-KRIT1 PPI by HNA did not meaningfully change in the presence of excess free lysine (Figure 2A). Next, we evaluated whether other known lysine-reactive electrophiles may inhibit the HEG1-KRIT1 interaction. A library of 44 commercially available lysine-reactive fragments (see Supporting Information), including various vinylsulfones, vinylsulfonamides, acrylamides, sulfonyl fluorides, cyanamides, activated nitriles, thioesters, sultone esters, salicylaldehydes, and succinimides, along with a set of three synthesized 1-substituted-2-naphthol derivatives, were evaluated for inhibition of the HEG1-KRIT1 interaction. As summarized in Figure 2B, and in stark contrast to HNA, 50 μM of the lysine-reactive fragments did not inhibit the interaction, suggesting that these reactive electrophiles do not covalently modify Lys$^{720}$. These findings, compounded with prior X-ray and SAR data, indicate that although the HNA does not appear to be a hot, indiscriminate electrophile, and although the Lys$^{720}$ does not appear to be inherently reactive, the binding of HNA within the HEG1 binding domain of KRIT1 results in the specific modification of Lys$^{720}$.

Molecular Dynamics Simulations Indicate Important Interactions between HNA and Three KRIT1 Lys Residues. Computational studies based on molecular dynamics (MD) using Glide-MD and Covalent-MD workflows indicated that, in addition to Lys$^{720}$, two other lysine residues within the HEG1 binding domain of KRIT1, namely Lys$^{727}$ and Lys$^{729}$, interact with HNA by combining $\pi$-cation and H-bond interactions (Figure 2C,D). These data suggest that the observed specificity of the KRIT1-HNA interaction may depend on the cooperative interactions with both Lys$^{727}$ and

**RESULTS**

Optimization of a HEG1-KRIT1 Time-Resolved Fluorescence Polarization Assay. To evaluate the binding kinetics of HNA inhibitors, a fluorescence polarization (FP) time-resolved assay that uses a recombinant FERM domain (residues 417–736) of KRIT1 and a fluorescence-tagged HEG1 cytoplasmic tail (Cy5-HEG1 7-mer peptide) was developed (Supporting Information). Using HNA as a test compound, the FP data, expressed as millipolarization (mP) units, were obtained every 10 min over the course of 4–7 h. The binding affinity ($K_D$) for KRIT1 for the HEG1 probe was examined by following the change in polarization signal as a function of a matrix of five probe concentrations and four KRIT1 concentrations, which produced a best-fit probe $K_D$ of 13 nM. Evaluation of the kinetics of HNA as a KRIT1-HNA inhibitor using the FP assay suggested that, at lower HNA concentrations (<3 μM), equilibrium could not be reached, even after 7 h of incubation. Thus, for practical purposes, a 4-h incubation time was established as the standard assay time for non-kinetic $IC_{50}$ evaluations. From these FP assay conditions, the dose–response curve of HNA resulted in an $IC_{50}$ value of 8.14 μM, comparable to previously reported data obtained using the flow cytometry assay (3.09 μM).14

The HNA-KRIT1 Interaction Demonstrates a Relatively High Specificity and Selectivity. To evaluate the specificity and selectivity of the HNA binding to KRIT1, we asked whether the imine formation between HNA and Lys$^{720}$ was driven primarily by the intrinsic reactivity of the aldehyde moiety or the KRIT1 Lys$^{720}$. We first determined whether the inhibition activity of the HNA inhibitor could be reduced upon co-incubation of the compound with free lysine (50 μM) in the assay buffer. These co-incubation experiments revealed that the inhibition of HEG1-KRIT1 PPI by HNA did not meaningfully change in the presence of excess free lysine (Figure 2A). Next, we evaluated whether other known lysine-reactive electrophiles may inhibit the HEG1-KRIT1 interaction. A library of 44 commercially available lysine-reactive fragments (see Supporting Information), including various vinylsulfones, vinylsulfonamides, acrylamides, sulfonyl fluorides, cyanamides, activated nitriles, thioesters, sultone esters, salicylaldehydes, and succinimides, along with a set of three synthesized 1-substituted-2-naphthol derivatives, were evaluated for inhibition of the HEG1-KRIT1 interaction. As summarized in Figure 2B, and in stark contrast to HNA, 50 μM of the lysine-reactive fragments did not inhibit the interaction, suggesting that these reactive electrophiles do not covalently modify Lys$^{720}$. These findings, compounded with prior X-ray and SAR data, indicate that although the HNA does not appear to be a hot, indiscriminate electrophile, and although the Lys$^{720}$ does not appear to be inherently reactive, the binding of HNA within the HEG1 binding domain of KRIT1 results in the specific modification of Lys$^{720}$.

Molecular Dynamics Simulations Indicate Important Interactions between HNA and Three KRIT1 Lys Residues. Computational studies based on molecular dynamics (MD) using Glide-MD and Covalent-MD workflows indicated that, in addition to Lys$^{720}$, two other lysine residues within the HEG1 binding domain of KRIT1, namely Lys$^{727}$ and Lys$^{729}$, interact with HNA by combining $\pi$-cation and H-bond interactions (Figure 2C,D). These data suggest that the observed specificity of the KRIT1-HNA interaction may depend on the cooperative interactions with both Lys$^{727}$ and
Lys\textsuperscript{724}. These interactions may aid in positioning the aldehyde moiety of the HNA in close proximity to Lys\textsuperscript{720}, thereby facilitating the formation of the imine adduct. In addition, and in agreement with our prior SAR studies which revealed that any further structural simplification of the HNA results in a dramatic loss in HEG1-KRIT1 PPI inhibition activity (e.g., the IC\textsubscript{50} value of salicylaldehyde was found to be >500 μM\textsuperscript{14}), the MD simulation data also indicated a difference in KRIT1 protein binding between HNA and salicylaldehyde, with the former compound maintaining a comparatively more stable conformation during the MD simulation (see Supporting Information, Figure S2). Thus, these results indicate that, compared to the HNA, the salicylaldehyde may not be able to form sufficiently stable interactions with the surrounding residues in the binding site and that the weaker templating effects may ultimately result in an inefficient covalent modification of Lys\textsuperscript{720}.

**Kinetic Characterization of HEG1-KRIT1 Inhibition by HNA and Related Analogs.** Kinetic data arising from the displacement of the Cy5-HEG1 probe from KRIT1 by HNA are consistent with a one-step binding mechanism, as the displacement kinetics at all HNA concentrations began at a probe-only FP value (Figure 2E). A global fit to the association ($k_{on}$) and dissociation constants ($k_{off}$) (using GraphPad Prism, San Diego, CA) captures the observed displacement kinetics at all of the tested HNA concentrations (Figure 2E). The overall binding affinity ($K_i$) of HNA was found to be 2.29 μM, with a relatively slow association constant of 0.0518 μM\textsuperscript{-1} h\textsuperscript{-1} and a dissociation rate of 0.119 h\textsuperscript{-1}, which resulted in a long residence time ($1/k_{off}$) of 8.42 h. Interestingly, the binding affinity of HNA for KRIT1 as determined by the FP assay was much stronger than the affinity of HNA for a generic lysine residue, such as N-\alpha-acetyl lysine (i.e., $K_d = 164$ mM, see Supporting Information, Figure S3). This dramatic difference in affinity (>70,000-fold) seems consistent with the critical role of the non-covalent interactions of HNA within the HEG1 binding domain of KRIT1 in promoting the formation of the imine adduct with Lys\textsuperscript{720}.

**Figure 2.** Characterization of HEG1-KRIT1 binding. (A) HEG1-KRIT1 inhibition by HNA in the absence (red) or presence (blue) of 50 μM lysine in the assay buffer. Data are represented as means ± SD, n = 3. (B) Percent inhibition caused by 50 μM lysine reactive fragments relative to 50 μM HNA. (C, D) Molecular dynamic simulations of HNA-KRIT1 binding using Glide-MD (C) and Covalent-MD (D) highlight the concerted interactions of the HNA with Lys\textsuperscript{475}, Lys\textsuperscript{720}, and Lys\textsuperscript{724} (PDB 6OQ3). (E) Kinetic traces of HEG1-KRIT1 inhibition by HNA indicate a one-step slow binding mechanism. The kinetic parameters were calculated from these kinetic traces, including $k_{on}$, $k_{off}$, residence time ($1/k_{off}$), and $K_i$ ($k_{off}/k_{on}$). Data are represented as means ± SD, n = 3.
Table 1. Acid Dissociation Constants ($pK_a$), HEG1-KRIT1 PPI Inhibition Activity, Binding Kinetics, and HEK293 Cytotoxicity of Test Compounds

<table>
<thead>
<tr>
<th>Cpd</th>
<th>Structure</th>
<th>$pK_a$ (calc: $pK_a^e$)</th>
<th>HEG1-KRIT1 PPI Assay</th>
<th>HEK293 CC50 at 48 h (pM)*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>IC$_{50}$ at 4 h (pM)$^f$</td>
<td>$k_{on}$ (pM$^{-1}$ h)$^{-1}$</td>
</tr>
<tr>
<td>1</td>
<td><img src="image1" alt="Structure 1" /></td>
<td>7.34 ± 0.02 (8.21)</td>
<td>8.14 ± 0.82</td>
<td>0.0518 ± 0.0021</td>
</tr>
<tr>
<td>2</td>
<td><img src="image2" alt="Structure 2" /></td>
<td>7.42 ± 0.03 (8.22)</td>
<td>3.96 ± 0.84</td>
<td>0.0504 ± 0.003</td>
</tr>
<tr>
<td>3</td>
<td><img src="image3" alt="Structure 3" /></td>
<td>6.81 ± 0.05 (8.22)</td>
<td>0.65 ± 0.12</td>
<td>0.645 ± 0.094</td>
</tr>
<tr>
<td>4</td>
<td><img src="image4" alt="Structure 4" /></td>
<td>ND (8.21)</td>
<td>0.47 ± 0.11</td>
<td>0.720 ± 0.108</td>
</tr>
<tr>
<td>5</td>
<td><img src="image5" alt="Structure 5" /></td>
<td>8.08 ± 0.08 (8.20)</td>
<td>0.69 ± 0.11</td>
<td>0.388 ± 0.075</td>
</tr>
<tr>
<td>6</td>
<td><img src="image6" alt="Structure 6" /></td>
<td>7.50 ± 0.02 (8.21)</td>
<td>0.94 ± 0.12</td>
<td>0.190 ± 0.033</td>
</tr>
<tr>
<td>7</td>
<td><img src="image7" alt="Structure 7" /></td>
<td>7.17 ± 0.09 (8.21)</td>
<td>1.22 ± 0.43</td>
<td>0.183 ± 0.018</td>
</tr>
<tr>
<td>8</td>
<td><img src="image8" alt="Structure 8" /></td>
<td>7.30 ± 0.06 (8.21)</td>
<td>1.83 ± 0.82</td>
<td>0.128 ± 0.018</td>
</tr>
<tr>
<td>9</td>
<td><img src="image9" alt="Structure 9" /></td>
<td>7.34 ± 0.12 (8.22)</td>
<td>2.75 ± 0.19</td>
<td>0.0885 ± 0.0065</td>
</tr>
<tr>
<td>10</td>
<td><img src="image10" alt="Structure 10" /></td>
<td>6.95 ± 0.12 (8.22)</td>
<td>2.21 ± 0.68</td>
<td>0.107 ± 0.009</td>
</tr>
</tbody>
</table>
Table 1. continued

<table>
<thead>
<tr>
<th>Cpd</th>
<th>Structure</th>
<th>pKₐ (calcd pKₐ)</th>
<th>HEG1-KRIT1 PPI Assay</th>
<th>HEK293 CC₅₀ at 48 h (µM)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>IC₅₀ (µM)</td>
<td>kₐ (µM⁻¹ h⁻¹)</td>
<td>kₐff (h⁻¹)</td>
</tr>
<tr>
<td>11</td>
<td></td>
<td>12.06 ± 4.61</td>
<td>0.0347 ± 0.0075</td>
<td>0.395 ± 0.113</td>
</tr>
<tr>
<td>12</td>
<td></td>
<td>7.02 ± 0.08</td>
<td>1.42 ± 0.32</td>
<td>0.155 ± 0.021</td>
</tr>
<tr>
<td>13</td>
<td></td>
<td>6.76 ± 0.10</td>
<td>0.79 ± 0.24</td>
<td>0.403 ± 0.086</td>
</tr>
<tr>
<td>14</td>
<td></td>
<td>7.38 ± 0.12, 9.17 ± 0.21</td>
<td>11.99 ± 1.09</td>
<td>0.0165 ± 0.0016</td>
</tr>
<tr>
<td>15</td>
<td></td>
<td>7.75 ± 0.08</td>
<td>1.18 ± 0.39</td>
<td>0.217 ± 0.027</td>
</tr>
<tr>
<td>16</td>
<td></td>
<td>ND (8.21)</td>
<td>0.24 ± 0.09</td>
<td>0.835 ± 0.147</td>
</tr>
</tbody>
</table>

*pKₐ values were determined by potentiometric titrations using a Sirius T3 (Pion, Inc.). Data are represented as means ± SD of three titrations. *Calculated pKₐ values estimated by ChemAxon. *Inhibition of the HEG1-KRIT1 PPI obtained using the fluorescence polarization assay after 4 h of incubation. Data are represented as means ± SD, n = 3. *Kinetic parameters obtained as a global fit of the association (kₐ) and dissociation (kₐff) constants across six or more inhibitor concentrations. Data are represented as means ± SD, n = 3. *Cytotoxicity vs HEK293 cells using resazurin as a redox indicator for cell viability. Data are represented as means ± SD, n = 3.

**HNA Is a Site-Directing Fragment That Could Be Employed in the Development of HEG1-KRIT1 PPI Inhibitors.** To evaluate the potential of the HNA as a site-directing fragment to identify HEG1-KRIT1 PPI inhibitors with potentially improved binding affinity and inhibition activity, we synthesized and screened a series of HNA derivatives bearing substitutions at the C6 or C7 position of the naphthalene ring (Table 1, 2–16). The C6 and C7 positions were selected for substitutions as an analysis of the available HNA-KRIT1 co-crystal structure indicated that these two positions may provide opportunities for analogs with improved complementarity to the HEG1 binding region of KRIT1 (see Supporting Information). Test compounds were evaluated for selected physicochemical properties (pKₐ), ability to inhibit the HEG1-KRIT1 interaction, binding kinetics, and HEK293 cytotoxicity (Table 1). All 14 new HNA derivatives tested exhibited comparable or improved inhibition activity in the PPI assay relative to the parent compound, 1, with IC₅₀ values ranging between 0.24 and 12.06 µM and Kᵢ values between 0.31 and 11.38 µM. Like the parent HNA, all derivatives followed an apparent one-step binding mechanism. Relative to HNA, except for analogs 2, 11, and 14, which exhibited slightly slower kₐ values (i.e., 0.0504, 0.0347, and 0.0165 µM⁻¹ h⁻¹, respectively, vs HNA’s 0.0518 µM⁻¹ h⁻¹), all other congeners exhibited moderately faster association kinetics, with kₐ values ranging from 0.0885 to 0.835 µM⁻¹ h⁻¹. Likewise, although most HNA derivatives were characterized by comparatively fast kₐff values ranging from 0.157 to 0.426 h⁻¹, which led to relatively shorter residence times from 2.35 to 6.36 h, several examples, such as 2, 7–10, and 14,
exhibited slower dissociation kinetics compared to HNA (0.119 h⁻¹), with $k_{off}$ values ranging from 0.0556 to 0.115 h⁻¹ and longer residence times of ~8.7–18 h. Finally, in cytotoxicity assays using HEK293 cells, all test compounds exhibited little or no cytotoxicity, with CC₅₀ values >30 μM.

Co-crystal Structures of HNA Analogs 3, 5, and 6 Bound to KRIT1 Reveal Binding Modes Similar to That of the Parent HNA Fragment. The co-crystal structures of 3, 5, and 6 in complex with KRIT1 revealed that these compounds exhibit similar binding modes as the parent HNA fragment, including the presence of the imine adduct between the aldehyde moiety of the ligands and the Lys exciting 720 of KRIT1 (top). All crystal structures also reveal the formation of additional interactions with residues near the binding site (bottom).

Co-crystal structures and functional effect of HEG1-KRIT1 inhibitors. (A–C) Co-crystal structures of 3 (A, PDB: 8T09), 5 (B, PDB: 8SU8), and 6 (C, PDB: 8T77) bound to KRIT1, all three of which reveal the formation of an imine between the aldehyde moiety of the ligands and the Lys exciting 720 of KRIT1 (top). All crystal structures also reveal the formation of additional interactions with residues near the binding site (bottom). (D) Effect of HEG1-KRIT1 inhibitors on the KLF2 and KLF4 gene expression in endothelial cells. Bar graphs show mRNA levels for KLF2 and KLF4 after 4-h incubation with 2, 3, and 5 relative to inactive control (i.e., 2-hydroxy-1-naphthoic acid). Means ± SEM, with n = 4, one-way ANOVA. *, p < 0.05; **, p < 0.01; ***, p < 0.001.
to upregulate the same transcription factors in HUVEC after 4 h was measured. With this short incubation time, the HNA derivative 2 increased KLF2 and KLF4 expression without reaching statistical significance. In contrast, analogs 3 and 5, which are characterized by faster association kinetics and lower IC_{50} values in the FP assay (Table 1), generated significant elevations in the expression of both KLF2 and KLF4 (Figure 3D).

**DISCUSSION**

The covalent reversible binding of small molecules to target proteins is a validated strategy in the discovery and development of pharmacological tools and candidate therapeutics that modulate PPIs. The PPI between HEG1 and KRIT1 is believed to play an important role in controlling vascular development and permeability under normal and pathological conditions. Genetic approaches have been instrumental in highlighting the fundamental cellular processes regulated by endothelial HEG1 and KRIT1 proteins. However, until recently, no examples of small-molecule inhibitors of this PPI had been reported. This situation changed with the identification of the HNA fragment as a *bona fide* inhibitor of the HEG1-KRIT1 PPI. The HEG1 binding domain of KRIT1 features three lysines, namely Lys^{714}, Lys^{720}, and Lys^{724}; based on point mutation studies, these residues are essential for the interaction between HEG1 and KRIT1. The HNA was found to form a reversible imine adduct with Lys^{720}, and SAR studies indicated that the HNA is the smallest/simplest 2-hydroxy-arylaldehyde that inhibits the HEG1-KRIT1 PPI.

To better characterize the HNA fragment and investigate its potential in site-directed screening of HEG1-KRIT1 PPI inhibitors, the specificity and the binding kinetics of the HNA-KRIT1 interaction were evaluated. The present data show that the HNA fragment, as well as the closely related derivatives (2−16), exhibit all of the key characteristics of targeted reversible covalent ligands, which, in the context of KRIT1, produce a specific and selective covalent modification of the solvent-exposed Lys^{720}, providing excellent control over localization. Moreover, our results show that, depending on the choice of substituents, the residence time of the HNA can be tuned to reach a relatively prolonged time of up to 18 h. To the best of our knowledge, this is the first report detailing the binding kinetics of a 2-hydroxy-arylaldehyde with a noncatalytic lysine residue. Although context-dependent, our findings demonstrate that 2-hydroxy-arylaldehydes can be useful in site-directed fragment-based drug discovery programs, including those that are based on a reversible covalent modification of a noncatalytic lysine residue.

**CONCLUSIONS**

2-Hydroxy-arylaldehydes are known to potentially form imine adducts with lysine residues. However, reports detailing the binding kinetics of these warheads are scarce. In this work, we characterize the binding kinetics of HNA, as well as a series of HNA derivatives, with a noncatalytic lysine residue of the KRIT1 protein. We also demonstrate that HNA can serve as a site-directing fragment that could be employed in the development of more potent KRIT1 ligands. Taken together, the results from these studies lay the foundation for the development of potent and selective HEG1-KRIT1 PPI inhibitors and, more broadly, illustrate the potential of aldimine chemistry in designing site-directed fragments for drug/probe discovery.

**ASSOCIATED CONTENT**

* Supporting Information
  The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acsptsci.3c00156.
  Experimental details concerning the fluorescence polarization assay; synthesis of test compounds, including NMR spectra; computational methods; X-ray crystallography; cytotoxicity assay; and pK_{d} determination reports (PDF)

**AUTHOR INFORMATION**

*Corresponding Authors*

Alexandre R. Gingras — Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla, California 92093, United States; Email: alexrgingras@gmail.com

Mark S. Hixon — Mark S. Hixon Consulting LLC, San Diego, California 92126, United States; Email: mark.s.hixon.consulting@gmail.com

Carlo Ballatore — Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California 92093, United States; orcid.org/0000-0002-2718-3850; Email: cballatore@health.ucsd.edu

*Authors*

Karol R. Francisco — Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla, California 92093, United States; Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California 92093, United States

Jessica Bruystens — Department of Pharmacology, University of California, San Diego, California 92161, United States

Carmine Varricchio — School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff CF103NB, U.K.; orcid.org/0000-0002-1673-4768

Sara McCurdy — Department of Medicine, University of California, San Diego, La Jolla, California 92093, United States

Jian Wu — Department of Pharmacology, University of California, San Diego, California 92161, United States

Miguel A. Lopez-Ramirez — Department of Medicine, University of California, San Diego, La Jolla, California 92093, United States; Department of Pharmacology, University of California, San Diego, California 92161, United States

Mark Ginsberg — Department of Medicine, University of California, San Diego, La Jolla, California 92093, United States

Connor R. Caffrey — Center for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California 92093, United States

Andrea Brancale — School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff CF103NB, U.K.; Vysoká Škola Chemicko-Technologická v Praze, Department of Organic Chemistry, Technická 5, Prague 16628, Czech Republic; orcid.org/0000-0002-9728-3419

Complete contact information is available at: https://pubs.acs.org/10.1021/acsptsci.3c00156
Author Contributions

Notes
The authors declare the following competing financial interest(s): Declaration of Interests. C.B., A.R.G., M.G., and K.R.F. are inventors in a patent application (#US Patent App. 17/611,036 pending to University of California and University of New Mexico) that covers HNA derivatives.

ACKNOWLEDGMENTS
Financial support for this work was provided, in part, by the UCSD Academic Senate RS164R-GINGRAS (to A.R.G.), the UC Multi-Campus Research Program MRP-17-45490 (to CARING T32 Training Grant T32AI007036 (to K.R.F.), the M.A.L.-R. and C.B. provided resources; K.R.F. and C.B. wrote the manuscript; all authors reviewed and edited the manuscript.

REFERENCES